Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
117.23
-1.41 (-1.19%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,963,081
Open
118.90
Bid (Size)
117.01 (5)
Ask (Size)
117.25 (6)
Prev. Close
118.64
Today's Range
116.29 - 119.20
52wk Range
99.14 - 134.63
Shares Outstanding
2,531,374,696
Dividend Yield
2.49%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Today 8:00 EDT
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
September 18, 2024
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+3.52%
+3.52%
1 Month
+1.82%
+1.82%
3 Month
-9.59%
-9.59%
6 Month
-5.17%
-5.17%
1 Year
+9.24%
+9.24%
More News
Read More
Behind the Scenes of Merck & Co's Latest Options Trends
September 18, 2024
Via
Benzinga
NYSE:MRK: good value for what you're paying.
September 18, 2024
Via
Chartmill
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
Via
The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
September 18, 2024
From
Merck & Co., Inc.
Via
Business Wire
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
Via
Benzinga
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
Via
The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Via
Benzinga
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
September 17, 2024
From
Daiichi Sankyo
Via
Business Wire
A Closer Look at 8 Analyst Recommendations For Merck & Co
September 16, 2024
Via
Benzinga
Where Will Merck Stock Be in 5 Years?
September 14, 2024
Via
The Motley Fool
Merck & Co Unusual Options Activity
September 13, 2024
Via
Benzinga
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
September 16, 2024
Via
MarketBeat
Exposures
COVID-19
Product Safety
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
September 16, 2024
Via
Benzinga
Merck Scores Two Key Victories With Keytruda In Women's Cancers
September 15, 2024
Via
Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat Week in Review – 9/9 - 9/13
September 14, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
September 13, 2024
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.